Ceres Receives $430K from Gates Foundation for Ebola Test
Complete the form below to unlock access to ALL audio articles.
Ceres Nanosciences, Inc. announced the commencement of a development program, funded by the Gates Foundation, to use Ceres’ Nanotrap® particle technology to develop a new method of detecting the presence of the Ebola Virus in saliva. During the four month performance of this program, Ceres will work in close collaboration with George Mason University (Mason) and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to assess the ability of the Nanotrap technology to develop a more sensitive and safe Ebola virus detection method which uses saliva instead of blood.
Ceres, a biotechnology company located in northern Virginia, has developed and commercialized a novel nanoparticle technology, the “Nanotrap®”, which provides powerful biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs.
The Nanotrap technology was invented at George Mason University under funding from the National Institutes of Health (NIH) for biomarker discovery applications, and currently is being developed into commercial products by Ceres with continuing support from NIH, Defense Advanced Research Projects Agency (DARPA), Department of Homeland Security (DHS), and the Commonwealth of Virginia.
The combined team of Ceres, Mason and USAMRIID will bring forward world-class research capabilities and resources to execute this project on a rapid schedule to address the dire need for better testing methods for Ebola.
“Detection and confirmation of the Ebola virus is limited by issues inherent in collecting blood samples for testing. These include exposure risk, lack of adequately trained personnel, sample storage requirements, and, in some cases, cultural objections towards blood collection. The potential increased sensitivity afforded by Nanotrap sample processing in saliva could enable safer, earlier and more accurate detection and response during an outbreak”, said Ross Dunlap, CEO of Ceres.
“The effective detection of Ebola, using a non-invasive sample collection method like saliva collection, coupled with a highly sensitive diagnostic test, all enabled by our Nanotrap particle technology, presents a very compelling solution for rapid identification of infected individuals at earlier stage of infection”, said Dr. Emanuel Petricoin, Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University and co-founder of Ceres.
